Premium
Molecular Biomarkers in Non‐small Cell Lung Cancer – pointing the way to better outcomes from treatment
Author(s) -
ACKLAND Stephen
Publication year - 2009
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2009.01260.x
Subject(s) - lung cancer , medicine , erlotinib , gefitinib , pemetrexed , cetuximab , oncology , vinorelbine , gemcitabine , cancer , adenocarcinoma , disease , epidermal growth factor receptor , chemotherapy , colorectal cancer , cisplatin
Lung cancer is one of the most common malignancies in the world. In Australia, lung cancer accounts for 8500 new cases pa, the fifth most common cancer. In addition it is seldom ever cured, with the vast majority of patients succumbing from their disease, accounting for 7000 deaths pa in Australia, the commonest cause of cancer death. In developed countries like Australia, trends in smoking habits are leading to decreasing incidence but it still has a substantial health impact. On the contrary lung cancer has a sharply increasing incidence in developing countries, where it is destined to become a major health problem, including in many Asia Pacific region countries. Most cases of lung cancer are classified as non-small cell lung cancer (NSCLC)